S. Telang

598 total citations
14 papers, 465 citations indexed

About

S. Telang is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, S. Telang has authored 14 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in S. Telang's work include Cancer, Hypoxia, and Metabolism (7 papers), Cancer-related Molecular Pathways (4 papers) and CAR-T cell therapy research (3 papers). S. Telang is often cited by papers focused on Cancer, Hypoxia, and Metabolism (7 papers), Cancer-related Molecular Pathways (4 papers) and CAR-T cell therapy research (3 papers). S. Telang collaborates with scholars based in United States, India and Türkiye. S. Telang's co-authors include Jason Chesney, Amy Clem, Abdullah Yalçın, Brian F. Clem, John W. Eaton, Andrew N. Lane, Alden C. Klarer, Julie O’Neal, Richard Bucala and Yoannis Imbert-Fernandez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

S. Telang

13 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Telang United States 7 337 254 98 42 40 14 465
Hyo-Eun Moon South Korea 8 297 0.9× 144 0.6× 93 0.9× 37 0.9× 32 0.8× 9 420
Jung Yoo South Korea 14 400 1.2× 107 0.4× 122 1.2× 51 1.2× 28 0.7× 19 529
Zhiwei Chen China 11 294 0.9× 128 0.5× 110 1.1× 27 0.6× 38 0.9× 24 404
Emily Montal United States 10 352 1.0× 252 1.0× 60 0.6× 49 1.2× 37 0.9× 14 476
Kerstin Hölzer Germany 13 330 1.0× 90 0.4× 63 0.6× 52 1.2× 33 0.8× 23 478
Hirofumi Akashi Japan 11 329 1.0× 169 0.7× 140 1.4× 42 1.0× 17 0.4× 17 573
Douglas B. Fox United States 7 358 1.1× 191 0.8× 117 1.2× 33 0.8× 31 0.8× 8 505

Countries citing papers authored by S. Telang

Since Specialization
Citations

This map shows the geographic impact of S. Telang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Telang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Telang more than expected).

Fields of papers citing papers by S. Telang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Telang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Telang. The network helps show where S. Telang may publish in the future.

Co-authorship network of co-authors of S. Telang

This figure shows the co-authorship network connecting the top 25 collaborators of S. Telang. A scholar is included among the top collaborators of S. Telang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Telang. S. Telang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Telang, S., Manisha Desai, Amruta Shelar, et al.. (2023). Opaque cell-specific proteome ofCandida albicansATCC 10231. Medical Mycology. 61(7). 1 indexed citations
2.
3.
Adamkin, David H., et al.. (2015). Comparison of lactoferrin activity in fresh and stored human milk. Journal of Perinatology. 36(3). 207–209. 24 indexed citations
4.
Clem, Brian F., Julie O’Neal, Alden C. Klarer, S. Telang, & Jason Chesney. (2015). Clinical development of cancer therapeutics that target metabolism. QJM. 109(6). 367–372. 26 indexed citations
5.
Yalçın, Abdullah, Brian F. Clem, Yoannis Imbert-Fernandez, et al.. (2014). 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death and Disease. 5(7). e1337–e1337. 155 indexed citations
6.
Clark, John S., Yoannis Imbert-Fernandez, Jason Chesney, & S. Telang. (2014). The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts. Cancer & Metabolism. 2(S1). 1 indexed citations
7.
Chesney, Jason & S. Telang. (2013). Regulation of Glycolytic and Mitochondrial Metabolism by Ras. Current Pharmaceutical Biotechnology. 14(3). 251–260. 19 indexed citations
8.
Chesney, Jason, et al.. (2011). Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma.. Journal of Clinical Oncology. 29(15_suppl). 2507–2507. 4 indexed citations
9.
Yalçın, Abdullah, Brian F. Clem, Amy Clem, et al.. (2009). Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene. 29(1). 139–149. 82 indexed citations
10.
11.
Clem, Brian F., S. Telang, Amy Clem, Umesh Goswami, & Jason Chesney. (2009). Inhibition of 6-phosphofructo-2-kinase suppresses breast tumor growth in vivo.. Cancer Research. 69(2_Supplement). 3064–3064. 1 indexed citations
12.
Chesney, Jason, Mary Ann Rasku, Amy Clem, et al.. (2008). Transient T-cell depletion causes regression of melanoma metastases. Journal of Clinical Oncology. 26(15_suppl). 9030–9030. 2 indexed citations
13.
Telang, S., Abdullah Yalçın, Amy Clem, et al.. (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene. 25(55). 7225–7234. 136 indexed citations
14.
Chesney, Jason, et al.. (2006). DAB(389)IL2 (denileukin diftitox) suppresses growth of melanoma metastases. Journal of Clinical Oncology. 24(18_suppl). 18010–18010. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyo-Eun Moon Breakdown of academic impact, for papers by Jung Yoo Breakdown of academic impact, for papers by Zhiwei Chen Breakdown of academic impact, for papers by Emily Montal Breakdown of academic impact, for papers by Kerstin Hölzer Breakdown of academic impact, for papers by Hirofumi Akashi Breakdown of academic impact, for papers by Douglas B. Fox
Rankless by CCL
2026